Rakesh K. Jain

Rakesh K. Jain is the Andrew Werk Cook Professor of Tumor Biology at Harvard Medical School and Director of the Steele Laboratories for Tumor Biology at Massachusetts General Hospital. He is the world's foremost authority on tumor physiology, vasculature, and the physical barriers that impede drug delivery in solid tumors. Jain's landmark contribution — developed over three decades of quantitative tumor biology research — is the concept of "vascular normalization." He established that the blood vessels within tumors are structurally and functionally abnormal: they are tortuous, leaky, poorly pericyte-covered, and inefficiently perfused. Rather than simply attempting to destroy all tumor vessels (anti-angiogenic therapy, as proposed by Judah Folkman), Jain proposed and demonstrated that transient normalization of the tumor vasculature — using low doses of anti-VEGF or anti-VEGFR agents — can actually improve drug delivery, reduce hypoxia, decrease immunosuppression, and enhance the efficacy of chemotherapy, radiation, and immunotherapy. His bioengineering approach to tumor physiology has also characterized the elevated interstitial fluid pressure (IFP) within tumors — caused by leaky vasculature and absent lymphatics — as a critical barrier to macromolecular drug penetration. He has developed mathematical models and imaging methods to measure and predict drug transport in solid tumors, guiding clinical trial design and dosing strategies for nano-therapeutics. Jain's more recent work has focused on the immunosuppressive tumor microenvironment, showing that vascular normalization not only improves drug delivery but also restores immune cell infiltration and function. He demonstrated that anti-VEGF therapy increases CD8+ T cell infiltration into tumors, synergizing with checkpoint immunotherapy — findings that directly motivated approved combination regimens. He has also explored how mechanical forces (solid stress from tumor growth) compress blood and lymph vessels, further limiting perfusion and immune access. Jain has published over 800 papers with more than 100,000 citations and trained over 200 scientists. He has received every major award in biomedical engineering and oncology.

Rakesh K. Jain 是哈佛医学院的肿瘤生物学教授和麻省总医院Steele肿瘤生物学实验室主任，是肿瘤生理学、脉管系统以及阻碍实体肿瘤药物递送的物理屏障领域的世界级权威。 他的标志性贡献是"血管正常化"概念——证明使用低剂量抗VEGF药物瞬时正常化肿瘤脉管系统，可以改善药物递送、减少缺氧、降低免疫抑制并增强化疗、放疗和免疫治疗的疗效。他在肿瘤间质液压和机械力方面的研究为理解实体肿瘤中大分子药物渗透的物理屏障提供了定量框架。